LATE BREAKING SUBMISSION DEADLINE: May 30, 2024, 11:30PM EST

  • Late breaking abstracts are NOT eligible for poster awards.
  • ALL presenting authors must register and pay to attend the Symposium to present their poster.
  • Please send a Word file of your submission directly to: csps@intertaskconferences.

FORMAT

Maximum of 300 words - prepare the main text under the bolded headings:
Purpose
Methods
Results
Conclusion

REGULAR SUBMISSION DEADLINE: March 31, 2024, 11:30PM EST

ALL presenting authors must register and pay to attend the Symposium by May 3 or advise the Abstract Coordinator of an alternate presenting author. Presenting authors not registered by this day will have their submissions automatically withdrawn.

NON-TRAINEE SUBMISSIONS
Submissions meeting the minimum criteria will be invited to display a poster at the Symposium on Tuesday, June 11.

TRAINEE SUBMISSIONS
Accepted submissions will be invited to display a poster at the Symposium on Wednesday, June 12 OR Thursday, June 13.

POSTER FORMAT
Posters will be displayed on Velcro panels, 48 inches high by 96 inches wide.

TRAINEE POSTER AWARDS
To be considered for a Trainee Poster Award, you must be a member in good standing of CSPS or CC-CRS and indicate this during the submission process. (Membership will be verified). If you wish your poster to be considered for CSPS trainee poster awards at the Symposium, a .pdf file of your poster must be submitted online by Friday, May 3 - the link for submission will be provided later to all accepted abstract authors. Please review awards eligibility criteria.

IMPORTANT DATES
Submission deadline: March 31, 2024

Acceptance for abstracts NOT requiring revisions: April 18, 2024
Notification of abstracts requiring revisions: April 15 2024
Revisions completed: April 19, 2024
Acceptance notification for revised abstracts: April 28, 2024

ABSTRACT REVIEW
All submissions will be reviewed by a Scientific Review Committee. Posters presented should contain original work. In exceptional cases, work presented elsewhere within the last 12 months may be considered. Such work must be highly original and deemed of high importance by the abstract review committee to merit a second presentation. Work presented elsewhere must also contain the following acknowledged at the end of the abstract: the name of the meeting, the date of the original presentation, and reference to the publication if abstract has been published. Only those abstracts and posters that have not been presented elsewhere can be considered for CSPS Trainee Poster Awards.

PUBLICATION
All abstracts will be published in the Journal of Pharmacy & Pharmaceutical Sciences following the Symposium provided the author has registered to attend the symposium.

Instructions for Submitting an Abstracts - Please read carefully

  • The length of the body of the abstract should be 200 to 300 words maximum.
  • Abstracts must be submitted in English, must contain an adequate body of data, and be free of typographical errors. Please proofread your submission. If accepted, it will be appear in the Journal as submitted.
  • Prepare the main text under the bolded headings: Purpose, Methods, Results, Conclusion.
  • A small table of data or small figure may be uploaded.

For additional information please contact Abstract Coordinator at csps@intertaskconferences.com.

SAMPLE ABSTRACT:

The Effect of Inflammation on Expression of β1, β2, and β3-adrenoreceptors in Rat Heart

Forugh Sanaee and Fakhreddin Jamali. Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Alberta, Canada

Purpose: Inflammation reduces pharmacological response to β-adrenoreceptor (β-AR) blockers such as propranolol even in the presence of high concentrations. This decrease in potency has been shown due to be caused by downregulation of β1- AR. Recently, however, we have shown that pre-adjuvant arthritis (Pre-AA) fails to decrease responsiveness to nebivolol, a third generation β1- and β2-blocker with NO- generating property via β3-AR agonistic activity. The aim of this study was to investigate the effect of reduced expression of β1-AR on response to nebivolol.

Method: We studied expression of β1, β2 and β3-AR in two groups of male Sprague-Dawley rats (n=4 each), Control and Inflamed. On day 0, rats received single injections of 0.2 mL of either Mycobacterium butyricum in squalene (Inflamed) or 0.9% normal saline (Control). On day 15, when pre-adjuvant arthritis was confirmed, rats were anesthetized and incisions were made; hearts collected and immediately frozen in liquid nitrogen and stored at -80º C until analyzed. Western immunoblot was used to determine the protein levels of the β1, β2 and β3 subunits of β-AR in the rat heart. β-actin was used as a loading control.

Results: As we expected, the relative density of β1-AR protein was significantly reduced in inflamed animals as compared with control rats (control: inflamed; 2.27±0.55 vs. 1.45±0.31, p=0.035) while that of β2-AR and β3-AR were not significantly influenced by inflammation (control: inflamed; β2-AR: 0.9±0.02 vs. 0.89±0.13 and β3-AR: 2.5±0.38 vs. 2.12±0.25).

Conclusion: The lack of effect of inflammation on response to nebivolol appears to be due to the drug’s nitric oxide donating property via β3 and β2-AR stimulation as under our experimental conditions, the level of β2- and β3-AR remains unaffected by inflammation despite the observed down-regulation of β1- AR.

Modifying an Existing Submission

If you have been requested to made edits to an existing submission, or to upload a poster:

1. Click on the upper right corner of the web browser window (silhouette of a person)

2. Select "My Submissions"

3. Select "View Form"

4. Edit the abstract, click Save Form

Modifying an Existing Submission

View Form

View Form
Powered by